NEW YORK – Verastem Oncology on Monday announced the launch of a Phase II clinical trial of its investigational MEK and pan-RAF inhibitor, VS-6766, as a treatment for recurrent, low-grade serous ovarian cancer patients, including those harboring KRAS mutations.